| Gamma-Secretase Complex (γ-Secretase) | |
|---|---|
| Catalytic Subunit | Presenilin-1 (PSEN1) or Presenilin-2 (PSEN2) |
| Subunits | Presenilin, Nicastrin, APH-1, PEN-2 |
| UniProt (PSEN1) | P49768 |
| PDB | 5A63, 6IDF, 5FN2 |
| Complex Weight | ~230 kDa |
| TM Domains | 20 transmembrane helices (total) |
| Localization | Plasma membrane, endosomes, ER-Golgi |
| Enzyme Class | Intramembrane aspartyl protease (GxGD type) |
| Diseases | Alzheimer's Disease |
Gamma Secretase Complex (Γ Secretase) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gamma-secretase (γ-secretase) is a multi-subunit intramembrane-cleaving protease complex that catalyzes the final proteolytic step in the production of [Amyloid-Beta (Aβ)[/proteins/Amyloid-Beta peptides from [amyloid precursor protein (APP[/proteins/app-protein. The complex consists of four essential transmembrane protein subunits: [presenilin[/proteins/presenilin-1 (PS1 or PS2, the catalytic component), nicastrin (NCT), anterior pharynx-defective 1 (APH-1), and presenilin enhancer 2 (PEN-2) (Edbauer et al., 2003). γ-Secretase is one of the most important drug targets in [Alzheimer's disease[/diseases/alzheimers research, though its broad substrate repertoire — cleaving over 150 type I transmembrane proteins including Notch receptors — has made therapeutic modulation exceedingly challenging (Bhatt et al., 2022).
The γ-secretase complex assembles from four obligate subunits with a 1:1:1:1 stoichiometry. Assembly occurs in the endoplasmic reticulum (ER), with the mature, active complex trafficked to the plasma membrane and endosomes.
The atomic-resolution structure of human γ-secretase was first solved by cryo-electron microscopy (cryo-EM) at 3.4 Å resolution (PDB: 5A63), revealing the architecture of the intact complex (Bai et al., 2015):
Subsequent substrate-bound structures (PDB: 6IDF — γ-secretase with Notch; 5FN2 — with DAPT inhibitor) revealed how substrates enter a lateral gate between TMD2 and TMD6, unfold their transmembrane helix, and present the scissile bond to the catalytic aspartates in a β-strand conformation (Zhou et al., 2019).
The complex exhibits remarkable conformational flexibility, with TMD2 and TMD6 acting as dynamic gatekeepers. This plasticity explains how γ-secretase can accommodate diverse substrates and underlies the variable cleavage positions that determine [Aβ[/entities/amyloid-beta peptide length.
γ-Secretase is not merely an "[Aβ[/entities/amyloid-beta-generating machine" — it is an essential protease that processes a vast repertoire of over 150 type I transmembrane substrates after their ectodomains have been shed by metalloproteases or other sheddases. Key substrates include:
The most critical non-[APP[/genes/app substrate. γ-Secretase releases the Notch intracellular domain (NICD) from Notch1-4 receptors, which translocates to the nucleus and activates transcription of Hes and Hey family genes. Notch signaling is essential for:
Sequential cleavage of [APP[/proteins/app-protein C-terminal fragments (C99 and C83) generates [Aβ[/entities/amyloid-beta peptides of varying lengths and the [APP[/genes/app intracellular domain (AICD). The complex performs processive cleavage, initially cutting at the ε-site (Aβ48 or Aβ49), then trimming in ~3-residue steps (Aβ48→45→42→38 or Aβ49→46→43→40) (Takami et al., 2009).
γ-Secretase is central to [Alzheimer's disease[/diseases/alzheimers pathogenesis through two mechanisms:
Aβ generation: The enzyme produces the toxic [Aβ42[/proteins/Amyloid-Beta peptide from [APP[/proteins/app-protein-derived C99 substrate. The ratio of Aβ42/Aβ40 is a critical determinant of [amyloid aggregation[/mechanisms/amyloid-aggregation and plaque formation.
Familial AD mutations: Over 300 [PSEN1[/genes/psen1 mutations and ~50 [PSEN2[/genes/psen2 mutations cause [familial Alzheimer's Disease]. Most FAD mutations do not simply increase total Aβ production; rather, they impair the processive trimming activity of γ-secretase, causing premature release of longer, more aggregation-prone Aβ42 and Aβ43 peptides while reducing production of shorter Aβ38 and Aβ40 species (Szaruga et al., 2017). This "loss-of-function for processivity" model explains why [PSEN1[/entities/psen1 mutations increase the Aβ42/Aβ40 ratio.
Gain-of-function mutations in Notch pathway components (including γ-secretase subunits) have been identified in T-cell acute lymphoblastic leukemia (T-ALL), making γ potential cancer therapeutics.
Several GSIs advanced to clinical trials for Alzheimer's Disease but all failed:
GSMs represent a more refined approach: rather than blocking all cleavage, they allosterically shift the cleavage position to favor production of shorter, less toxic Aβ species (Aβ37, Aβ38) while reducing Aβ42, without affecting Notch processing. Second-generation GSMs with improved potency and brain penetrance are in preclinical and early clinical development.
Emerging approaches include antisense oligonucleotides and CRISPR-based strategies to correct specific PSEN1 mutations in familial AD patients, preserving normal γ-secretase function while eliminating the pathogenic allele.
[Proteins Index[/proteins
[amyloid-beta[/entities/amyloid-beta
[APP Processing[/mechanisms/app-processing
[Alzheimer's disease[/diseases/alzheimers
[presenilin-1[/genes/psen1
[presenilin-2[/genes/psen2
The study of Gamma Secretase Complex (Γ Secretase) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.